Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. PTC Therapeutics, Inc.
  6. Summary
    PTCT   US69366J2006

PTC THERAPEUTICS, INC.

(PTCT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
37.37(c) 36.27(c) 35.87(c) 35.98(c) 35.87 Last
1 216 683 524 691 601 324 400 712 174 447 Volume
-1.89% -2.94% -1.10% +0.31% -0.31% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 480 M - -
Net income 2021 -498 M - -
Net cash position 2021 337 M - -
P/E ratio 2021 -5,57x
Yield 2021 -
Sales 2022 665 M - -
Net income 2022 -324 M - -
Net cash position 2022 261 M - -
P/E ratio 2022 -8,32x
Yield 2022 -
Capitalization 2 540 M 2 540 M -
EV / Sales 2021 4,59x
EV / Sales 2022 3,43x
Nbr of Employees 963
Free-Float 97,0%
More Financials
Company
PTC Therapeutics, Inc. is a science-driven global biopharmaceutical company. The Company is focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company's portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research... 
Read more
Sector
Biotechnology & Medical Research
Calendar
10/28 | 04:30pmEarnings Call
More about the company
Ratings of PTC Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about PTC THERAPEUTICS, INC.
10/18PTC THERAPEUTICS : BofA Securities Downgrades PTC Therapeutics to Underperform from Neutra..
MT
10/14PTC THERAPEUTICS : to Host Conference Call to Discuss Third Quarter 2021 Financial Results
PR
10/14PTC THERAPEUTICS : Celebrates Opening of Gene Therapy Manufacturing Facility
PR
10/14PTC Therapeutics Celebrates Opening of Gene Therapy Manufacturing Facility
CI
10/12PTC THERAPEUTICS : Tegsedi Receives Innovative Drug Category Pricing in Brazil
AQ
10/11PTC THERAPEUTICS' : Tegsedi Receives Innovative Drug Category Pricing in Brazil; Shares Ri..
MT
10/11PTC THERAPEUTICS : Tegsedi® Receives Innovative Drug Category Pricing in Brazil
PR
09/30PTC THERAPEUTICS : Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
09/29PTC THERAPEUTICS : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
09/23PTC THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form..
AQ
09/20PTC THERAPEUTICS : to Host Conference Call to Discuss Results of PTC518 Phase 1 Study for ..
PR
09/20PTC THERAPEUTICS : Says Translarna Therapy Delays Loss of Ambulation in Nonsense Mutation ..
MT
09/20PTC THERAPEUTICS : STRIDE Data Show Translarna™ Delays Loss of Ambulation by More Th..
PR
09/20PTC Therapeutics, Inc. Announces STRIDE Data Show Translarna Delays Loss of Ambulation ..
CI
09/07PTC THERAPEUTICS : Recognizes 2021 STRIVE Awards Recipients for Initiatives Supporting Duc..
PR
More news
News in other languages on PTC THERAPEUTICS, INC.
10/11Le Tegsedi de PTC Therapeutics reçoit le prix de la catégorie des médicaments innovants..
09/20Selon PTC Therapeutics, le traitement Translarna retarde la perte de mobilité dans la d..
2020Roche verse de nouveaux paiements d'étape à PTC
2020BOURSE ZURICH : le marché a entamé la semaine du bon pied
2020Roche verse 15 millions de dollars au laboratoire PTC Therapeutics
More news
Analyst Recommendations on PTC THERAPEUTICS, INC.
More recommendations
Chart PTC THERAPEUTICS, INC.
Duration : Period :
PTC Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PTC THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 35,98 $
Average target price 55,30 $
Spread / Average Target 53,7%
EPS Revisions
Managers and Directors
Stuart Walter Peltz Chief Executive Officer & Director
Emily Hill Chief Financial Officer
Michael Schmertzler Chairman
Neil Gregory Almstead Chief Technical Operations Officer
Mark Jerome Pykett Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
PTC THERAPEUTICS, INC.-41.05%2 540
GILEAD SCIENCES, INC.14.98%83 993
BIONTECH SE251.28%69 162
WUXI APPTEC CO., LTD.25.77%65 142
REGENERON PHARMACEUTICALS17.86%59 196
VERTEX PHARMACEUTICALS-20.84%48 536